抗厌氧菌抗生素、肠道菌群与脓毒症相关急性肾损伤
该研究通过回顾性队列(N=12,776)、工具变量分析(AKI发生N=3,036,缓解N=2,177)、匹配病例对照(N=372)及小鼠模型(N=53)四部分互补分析,探讨抗厌氧菌抗生素与脓毒症相关AKI的关系。回顾性队列中早期暴露于抗厌氧菌抗生素与脓毒症相关AKI风险独立增加61%(95%CI 37%-92%)相关。工具变量分析显示抗厌氧菌抗生素(哌拉西林-他唑巴坦)与AKI发生风险增加(HR 1.65,95%CI 1.18-2.30)及AKI缓解降低(HR 0.74,95%CI 0.61-0.88)相关。匹配病例对照显示肠道细菌密度增加及肠杆菌科和毛螺菌科富集可预测后续AKI发生;小鼠模型中肌酐升高与肠道菌群组成强相关(P<0.001),毛螺菌科相对丰度解释18%的血肌酐变异。结论认为抗厌氧菌抗生素与脓毒症AKI风险增加相关,可能通过调节肠道菌群介导。
要点
- 回顾性队列(N=12,776)中,脓毒症早期暴露于抗厌氧菌抗生素与脓毒症相关AKI风险独立增加61%相关(95%CI 37%-92%)。
- 工具变量分析中,抗厌氧菌抗生素(哌拉西林-他唑巴坦)与AKI发生风险增加相关(HR 1.65,95%CI 1.18-2.30)。
- 工具变量分析中,抗厌氧菌抗生素(哌拉西林-他唑巴坦)与AKI缓解降低相关(HR 0.74,95%CI 0.61-0.88)。
- 匹配病例对照(N=372)中,肠道细菌密度增加及肠杆菌科和毛螺菌科富集可预测后续AKI发生。
- 小鼠脓毒症模型(N=53)中,肌酐升高与肠道菌群组成强相关(P<0.001),毛螺菌科相对丰度解释18%的血肌酐变异。
适用人群与场景
- 脓毒症患者(回顾性队列N=12,776;工具变量分析AKI发生N=3,036、缓解N=2,177;匹配病例对照N=372)
- 小鼠脓毒症模型(N=53)
研究设计与关键结果
- 研究类型:回顾性队列、工具变量分析、匹配病例对照及小鼠模型四部分互补分析;回顾性队列N=12,776,工具变量分析AKI发生N=3,036、缓解N=2,177,匹配病例对照N=372,小鼠模型N=53。
- 回顾性队列:脓毒症早期暴露于抗厌氧菌抗生素与脓毒症相关AKI风险独立增加61%相关(95%CI 37%-92%)。
- 工具变量分析(利用2015-16年哌拉西林-他唑巴坦短缺):抗厌氧菌抗生素(哌拉西林-他唑巴坦)与AKI发生风险增加相关(HR 1.65,95%CI 1.18-2.30)。
- 工具变量分析:抗厌氧菌抗生素(哌拉西林-他唑巴坦)与AKI缓解降低相关(HR 0.74,95%CI 0.61-0.88)。
- 匹配病例对照:肠道细菌密度增加及肠杆菌科和毛螺菌科富集可预测后续AKI发生。
- 小鼠脓毒症模型:肌酐升高与供应商及肠道群落组成强相关(P<0.001 for all),毛螺菌科相对丰度解释18%的血肌酐变异。
证据类型、等级与局限
- 证据类型:回顾性队列、工具变量分析、匹配病例对照及小鼠模型。
- 局限:原文未报告局限性
对床旁实践的改变
- 作者认为抗厌氧菌抗生素与脓毒症AKI风险增加相关,可能通过调节肠道菌群介导。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
RATIONALE: Acute kidney injury (AKI) is a common complication of sepsis. Anti-anaerobic antibiotics, which deplete gut commensal bacteria, are common in the initial management of sepsis. Recent studies have reported an association between anti-anaerobic antibiotics and mortality, but the mechanisms underlying this relationship remain unknown.
OBJECTIVE: To determine whether anti-anaerobic antibiotics and gut microbiome disruption increase patient susceptibility to sepsis-associated AKI.
METHODS: We identified a cohort of patients with sepsis and performed four complementary analyses: 1) comparing AKI incidence among patients who did and did not receive early anti-anaerobic antibiotics, 2-3) two instrumental variable analyses using the 2015-16 piperacillin-tazobactam shortage to determine the effect of anti-anaerobic antibiotics on the onset and resolution of AKI, and 4) a matched case-control study comparing gut microbiota in septic patients who did and did not develop AKI. We then modeled sepsis in genetically-identical but microbially-heterogenous mice and compared creatinine elevation with gut microbiota.
MEASUREMENTS AND MAIN RESULTS: In a retrospective cohort study (N=12,776), early exposure to anti-anaerobic antibiotics was independently associated with a 61% increased risk of sepsis-associated AKI (95% CI-37%-92%). In instrumental variable analyses of AKI onset (N=3,036) and resolution (N=2,177), treatment with anti-anaerobic antibiotics (piperacillin-tazobactam) was associated with an increased hazard of AKI onset (HR-1.65, 95% CI-1.18-2.30) and decreased AKI resolution (HR-0.74, 95% CI-0.61-0.88). In a matched case-control study of gut microbiota in 372 patients with sepsis, increased gut bacterial density and enrichment with Enterobacteriaceae and Lachnospiraceae spp. predicted subsequent AKI onset. In a murine model of sepsis (N=53), creatinine elevation was strongly associated with vendor and gut community composition (P<0.001 for all), with relative abundance of Lachnospiraceae spp. explaining 18% of variation in serum creatinine.
CONCLUSIONS: Anti-anaerobic antibiotics are associated with increased risk of AKI in sepsis, potentially via modulation of the gut microbiome.
参考来源
- Winner KM, Chanderraj R, Nuppnau M, et al. Anti-Anaerobic Antibiotics, Gut Microbiota, and Sepsis-associated Acute Kidney Injury. Am J Respir Crit Care Med. 2025. PMID: 40737346. doi:10.1164/rccm.202411-2281OC
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。